CIK 0001622229 · Large accelerated filer
Cogent Biosciences, Inc.
Sign in to watch- Ticker
- COGT
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 465308248
- Phone
- 617-945-5576
- Business address
- 180 THIRD AVENUE, 4TH FLOOR, WALTHAM, MA
- Former names
- Unum Therapeutics Inc., Unum Therapeutics, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $1,689,493
- in 1 filing, $1.7M under 10b5-1 plans
Net −$1,689,493. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2023-06-07 | Ferrante Karen Jean Director | Grant or award · Stock Option (Right to Buy) | +36,700 | 36,700 | ||
| 2023-06-07 | Shegog Todd Director | Grant or award · Stock Option (Right to Buy) | +36,700 | 36,700 | ||
| 2023-06-07 | Ros Matthew Director | Grant or award · Stock Option (Right to Buy) | +36,700 | 36,700 | ||
| 2023-06-07 | Harwin Peter Evan Director | Grant or award · Stock Option (Right to Buy) | +36,700 | 36,700 | ||
| 2023-04-03 | Ferrante Karen Jean Director | Grant or award · Stock Option (Right to Buy) | +2,053 | 2,053 | ||
| 2023-04-03 | Ros Matthew Director | Grant or award · Stock Option (Right to Buy) | +1,900 | 1,900 | ||
| 2023-02-13 | Robinson John Edward Chief Scientific Officer | Grant or award · Stock Option (Right to Buy) | +160,000 | 160,000 | ||
| 2023-02-13 | Kearns Evan Chief Legal Officer | Grant or award · Stock Option (Right to Buy) | +140,000 | 140,000 | ||
| 2023-02-13 | Sachs Jessica Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +160,000 | 160,000 | ||
| 2023-02-13 | Green John L. Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +150,000 | 150,000 | ||
| 2023-02-13 | Robbins Andrew R President and CEO | Grant or award · Stock Option (Right to Buy) | +525,000 | 525,000 | ||
| 2023-01-03 | Ros Matthew Director | Grant or award · Stock Option (Right to Buy) | +1,792 | $7.19 | $13K | 1,792 |
| 2023-01-03 | Ferrante Karen Jean Director | Grant or award · Stock Option (Right to Buy) | +1,862 | $7.19 | $13K | 1,862 |
| 2022-10-03 | Ros Matthew Director | Grant or award · Stock Option (Right to Buy) | +1,419 | $9.08 | $13K | 1,419 |
| 2022-10-03 | Ferrante Karen Jean Director | Grant or award · Stock Option (Right to Buy) | +1,474 | $9.08 | $13K | 1,474 |
| 2022-07-01 | Ferrante Karen Jean Director | Grant or award · Stock Option (Right to Buy) | +2,279 | $5.87 | $13K | 2,279 |
| 2022-07-01 | Ros Matthew Director | Grant or award · Stock Option (Right to Buy) | +2,194 | $5.87 | $13K | 2,194 |
| 2022-06-30 | Sachs Jessica Chief Medical Officer | Grant or award | +622 | $7.40 | $5K | 622 |
| 2022-06-16 | Fairmount Funds Management LLC 10% owner | Purchase | +1,200,000 | $8.25 | $9.9M | 2,472,124 |
| 2022-06-07 | Ferrante Karen Jean Director | Grant or award · Stock Option (Right to Buy) | +30,700 | 30,700 |
Page 6 of 7 · 131 trades